Abstract：
OBJECTIVE: Although minimally invasive cardiac surgery (MICS) procedures are widely performed throughout Japan, nationwide data regarding treated cases are limited. Up-to-date results for cardiovascular surgery are vital for quality control in clinical practice. Presented here is the 2021 annual report based on data from the Japan Cardiovascular Surgery Database (JCVSD).
METHODS: Records noted in the JCVSD of patients who underwent mitral valve surgery, aortic valve replacement (AVR), coronary artery bypass grafting (CABG), atrial septum defect (ASD) closure, or cardiac tumor resection via right or left minithoracotomy, as well as thoracoscopic- or port-assisted, or robotic-assisted approaches, in 2021 were examined. Perioperative parameters including mortality and morbidity was evaluated.
RESULTS: The 30-day and in-hospital mortalities for isolated mitral valve repair (n = 1211) were 0.1% and 0.2%, respectively, while those for all mitral valve repair (n = 2017) were 0.05% and 0.2%, respectively. More than 100 facilities were found to perform fewer than five MICS mitral valve surgery cases per year. As for MICS-AVR, 30-day and in-hospital mortalities for isolated AVR (n = 818) were 0.5% and 0.5%, respectively, while those for all AVR (n = 987) were 0.6% and 1.1%, respectively. Additionally, those for MICS-CABG (n = 400) were 0.8% and 0.5%, respectively. Those for ASD (n = 183) and cardiac tumor (n = 96), were 0.5% and 0.5%, respectively, and 0% and 1.0%, respectively.
CONCLUSIONS: This is the first report of MICS results of procedures performed in Japan based on the 2021 JCVSD data. Additional results obtained with a similar data collection method are expected and details on MICS are being collected starting 2024.
METHODS: Records noted in the JCVSD of patients who underwent mitral valve surgery, aortic valve replacement (AVR), coronary artery bypass grafting (CABG), atrial septum defect (ASD) closure, or cardiac tumor resection via right or left minithoracotomy, as well as thoracoscopic- or port-assisted, or robotic-assisted approaches, in 2021 were examined. Perioperative parameters including mortality and morbidity was evaluated.
RESULTS: The 30-day and in-hospital mortalities for isolated mitral valve repair (n = 1211) were 0.1% and 0.2%, respectively, while those for all mitral valve repair (n = 2017) were 0.05% and 0.2%, respectively. More than 100 facilities were found to perform fewer than five MICS mitral valve surgery cases per year. As for MICS-AVR, 30-day and in-hospital mortalities for isolated AVR (n = 818) were 0.5% and 0.5%, respectively, while those for all AVR (n = 987) were 0.6% and 1.1%, respectively. Additionally, those for MICS-CABG (n = 400) were 0.8% and 0.5%, respectively. Those for ASD (n = 183) and cardiac tumor (n = 96), were 0.5% and 0.5%, respectively, and 0% and 1.0%, respectively.
CONCLUSIONS: This is the first report of MICS results of procedures performed in Japan based on the 2021 JCVSD data. Additional results obtained with a similar data collection method are expected and details on MICS are being collected starting 2024.
摘要：
目的：尽管微创心脏手术（MICS）在日本各地广泛使用，关于治疗病例的全国数据有限。心血管手术的最新结果对于临床实践中的质量控制至关重要。这里介绍的是基于日本心血管外科数据库（JCVSD）数据的2021年年度报告。
方法：JCVSD中记录的二尖瓣手术患者，主动脉瓣置换术(AVR),冠状动脉旁路移植术(CABG),房间隔缺损(ASD)封堵术,或通过右侧或左侧小切口切除心脏肿瘤，以及胸腔镜或端口辅助，或者机器人辅助方法，2021年进行了检查。评估围手术期参数，包括死亡率和发病率。
结果：隔离二尖瓣修复（n=1211）的30天死亡率和住院死亡率分别为0.1％和0.2％，分别,而所有二尖瓣修复（n=2017）的患者分别为0.05％和0.2％，分别。每年发现有100多家机构进行少于5例MICS二尖瓣手术。至于MICS-AVR，孤立性AVR（n=818）的30天和住院死亡率分别为0.5％和0.5％，分别,而所有AVR(n=987)分别为0.6%和1.1%，分别。此外,MICS-CABG(n=400)分别为0.8%和0.5%，分别。ASD（n=183）和心脏肿瘤（n=96），分别为0.5%和0.5%，分别,0%和1.0%，分别。
结论：这是根据2021年JCVSD数据在日本执行的程序的MICS结果的第一份报告。预计将使用类似的数据收集方法获得其他结果，并且从2024年开始收集有关MICS的详细信息。
方法：JCVSD中记录的二尖瓣手术患者，主动脉瓣置换术(AVR),冠状动脉旁路移植术(CABG),房间隔缺损(ASD)封堵术,或通过右侧或左侧小切口切除心脏肿瘤，以及胸腔镜或端口辅助，或者机器人辅助方法，2021年进行了检查。评估围手术期参数，包括死亡率和发病率。
结果：隔离二尖瓣修复（n=1211）的30天死亡率和住院死亡率分别为0.1％和0.2％，分别,而所有二尖瓣修复（n=2017）的患者分别为0.05％和0.2％，分别。每年发现有100多家机构进行少于5例MICS二尖瓣手术。至于MICS-AVR，孤立性AVR（n=818）的30天和住院死亡率分别为0.5％和0.5％，分别,而所有AVR(n=987)分别为0.6%和1.1%，分别。此外,MICS-CABG(n=400)分别为0.8%和0.5%，分别。ASD（n=183）和心脏肿瘤（n=96），分别为0.5%和0.5%，分别,0%和1.0%，分别。
结论：这是根据2021年JCVSD数据在日本执行的程序的MICS结果的第一份报告。预计将使用类似的数据收集方法获得其他结果，并且从2024年开始收集有关MICS的详细信息。
